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Abstract
Objective. Previous studies examining opioid dose
and overdose risk provide limited granularity by milli-
gram strength and instead rely on thresholds. We
quantify dose-dependent overdose mortality over a
large spectrum of clinically common doses. We also
examine the contributions of benzodiazepines and
extended release opioid formulations to mortality.
Design. Prospective observational cohort with one
year follow-up.
Setting. One year in one state (NC) using a con-
trolled substances prescription monitoring pro-
gram, with name-linked mortality data.
Subjects. Residential population of North Carolina
(n59,560,234), with 2,182,374 opioid analgesic
patients.
Methods. Exposure was dispensed prescriptions of
solid oral and transdermal opioid analgesics; per-
son-years calculated using intent-to-treat princi-
ples. Outcome was overdose deaths involving
opioid analgesics in a primary or additive role.
Poisson models were created, implemented using
generalized estimating equations.
Results. Opioid analgesics were dispensed to 22.8%
of residents. Among licensed clinicians, 89.6% pre-
scribed opioid analgesics, and 40.0% prescribed ER
formulations. There were 629 overdose deaths, half
of which had an opioid analgesic prescription active
on the day of death. Of 2,182,374 patients prescribed
opioids, 478 overdose deaths were reported (0.022%
per year). Mortality rates increased gradually across
the range of average daily milligrams of morphine
equivalents. 80.0% of opioid analgesic patients also
received benzodiazepines. Rates of overdose death
among those co-dispensed benzodiazepines and
opioid analgesics were ten times higher (7.0 per
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10,000 person-years, 95 percent CI: 6.3, 7.8) than
opioid analgesics alone (0.7 per 10,000 person years,
95 percent CI: 0.6, 0.9).
Conclusions. Dose-dependent opioid overdose risk
among patients increased gradually and did not
show evidence of a distinct risk threshold. There is
urgent need for guidance about combined classes
of medicines to facilitate a better balance between
pain relief and overdose risk.
Key Words. Opioids; Epidemiology; Overdose;
Dose–Response; Cohort Study; Prescriptions; Chronic
Pain; Risk Factors; Cloud Computing; Big Data
Introduction
The dose-dependent relationship between opioids and
fatal respiratory depression have been documented by
medical professionals for millennia [1–4]. In modern
times, the United States and Canada have the highest
per capita consumption of opioids in the world and the
highest overdose rates [5–10]. In contrast, in much of
the world opioid analgesics are unavailable even for
end-of-life pain control among cancer patients [11].
Ecologic studies suggest a near-linear association
between the total amount of opioids dispensed and
overdose morbidity and mortality [10,12–20]. Yet, fatal
and nonfatal overdoses are rarely reported even at high
doses in clinical trials [21–24]. Beyond ecologic studies
and clinical trials, several patient-level observational
studies have provided insight into opioid analgesic use
in routine clinical practice [25–34]. Direct comparison
between these studies is difficult because of variations
in whether deaths due to illicit drugs and suicide were
included, which opioids were considered in the expo-
sure, and whether relative effect measures included
opioid unexposed individuals in the reference group.
Most provide little to no information on the gradient of
risk above 200 mg per day of morphine equivalents
because these studies treat all higher doses the same,
despite the fact that medicine is routinely prescribed
above this level [35]. None reported the extent to which
the dose-dependent effect may be influenced by co-
prescribed benzodiazepines, a well-established risk fac-
tor for respiratory depression [36–38].
For reasons that are unclear, the notion has become
entrenched that 100 or 120 mg per day of morphine
equivalents is a “high dose” of opioid and is associated
with an inflection point of risk for overdose, despite
varying definitions of how average daily dose is calcu-
lated. Dose ranging within epidemiologic studies has
been limited due to sample size considerations [25–31].
The tendency of the scientific community to settle on
100 mg as a threshold for risk is not arbitrary, but rather
may be explained by the psychological phenomenon of
digit preference (e.g., preferentially choosing numbers
that end in 5 or 00), within the broader concept of
heaping [39], and the ease of risk communication. To
address this limitation, a prospective cohort study
among North Carolina residents was undertaken to
quantify population-based rates of dose-dependent
overdose mortality without an a priori threshold.
Patterns of clinical opioid analgesic utilization, focusing
on prescribers, prescriptions, and patients, with atten-
tion to opioid substance and formulation type were first
described. It was also hypothesized that the dose-
dependent risk of mortality associated with opioid anal-
gesics could partially be explained by additional attribut-
able risk from exposure to concurrently prescribed
benzodiazepines.
Methods
Study Design
The analysis was structured as a prospective population-
based cohort study of all NC residents alive in 2010.
Exposure was defined as having received a dispensed
prescription of an opioid analgesic for use in 2010. The
outcome was overdose death (both unintentional and
undetermined intent) involving opioid analgesics.
Data Sources
The North Carolina Controlled Substances Reporting
System (CSRS) is a state-mandated prescription moni-
toring program operating since 2007. CSRS data are
generated when prescriptions for a controlled substance
are dispensed at pharmacies in North Carolina, with
electronic systems that capture patient data (name and
birthdate), drug name, quantity of units, date of dispens-
ing, and prescriber and pharmacy Drug Enforcement
Agency (DEA) registration numbers. Data are stored
locally at the pharmacy and transmitted within two
weeks of dispensing to a central database managed by
the NC Division of Mental Health, Developmental
Disabilities and Substance Abuse Services
(DMHDDSAS). Due to federal regulations and state
laws, the CSRS does not include prescription data from
pharmacies in Veterans Administration and Department
of Defense facilities, Indian Health Service clinics, physi-
cian in-clinic dispensing, veterinary clinics, and outpa-
tient opioid dependence treatment programs.
Death certificate data from North Carolina’s State Center
for Health Statistics were used to identify overdoses, sup-
plemented with detailed electronic records from the
Office of the Chief Medical Examiner (OCME). All deaths
that occurred in North Carolina are certified by trained
medical examiners or attending physicians. Postmortem
serum toxicological analyses are conducted as part of
autopsy and included drug details for all major controlled
substances, differentiating between types of pharmaceut-
ical opioids and isomers of diacetylmorphine (heroin).
Data on the numbers of total licensed clinicians practic-
ing in the state were obtained from state medical licen-
sure boards, via the North Carolina Health Professions
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Data System stored at the Cecil G. Sheps Center for
Health Services Research, University of North Carolina
at Chapel Hill.
Data Linkage
Linkage between mortality and CSRS data were con-
ducted deterministically. For each overdose decedent,
prescriptions dispensed in the 365 days prior to death
were identified using the first five letters of the last name
and date of birth, confirmed by matching the first name,
full last name and date of birth as recorded on the
death certificate.
Exposure Definition
For prescription data, Figure 1 depicts the data cleaning
process. A total of 54,825,930 records for dispensed
prescriptions were available for 2009 through 2011.
First, 1,094,717 records were removed corresponding
to prescriptions dispensed to non-NC residents, records
with unknown or missing drug names, and
Figure 1 Data cleaning steps for prescription data used in study. Numbers in figure represent the unique count of
prescription records included or excluded at each data cleaning step.
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noncontrolled substances. Person-days were calculated
using a measure referred to as “days supply.” Days
supply is a legally required prescription element defined
by the prescriber, noted on the prescription, and incor-
porated in a field of the CSRS. Days supply was trun-
cated to 182 days for 1,228 (0.002%) prescriptions for
opioid analgesics of greater duration because these
illogical values fell outside of DEA rules for controlled
substances dispensing. Days supply was imputed for
5,369,748 prescription records (10%) with missing or
zero days supply by assigning the median days supply
from the rest of the dataset, matched by quantity and
National Drug Code (NDC) number, which encom-
passes strength, formulation, active ingredient and man-
ufacturer. Some records were excluded because the
quantity dispensed could not be determined
(n¼18,303; 0.033%) because this was a necessary
field for calculating daily opioid exposure.
Next, 21,448,986 prescriptions were positively identified
for solid oral or transdermal opioid analgesics labeled
for acute and chronic pain containing codeine, hydroco-
done, hydromorphone, fentanyl, methadone, morphine,
oxycodone, and oxymorphone. The active ingredient,
milligram strength, and formulation type (e.g., extended-
release/immediate-release, and solid oral/patch/liquid)
were determined by matching to NDC number. To max-
imize inclusion of data with incorrect or missing NDC
numbers, a natural language processing regular expres-
sions-based parser was run on the drug name field to
determine the active ingredient and formulation, created
using natural language processing via Perl Regular
Expressions. Discrepant records were individually adju-
dicated to determine the correct classification using the
FDA’s Orange Book as a reference. The total process
resulted in the identification of 7,393,375 prescription
records for opioid analgesics.
Of the eight opioid substances analyzed in this paper,
two were available only as IR (codeine, hydrocodone),
and five were available as both ER and IR (fentanyl,
hydromorphone, morphine, oxycodone, oxymorphone) in
2010. In tablet form, methadone is used for chronic pain
management, and as a liquid for management of opioid
dependence; methadone was included in the ER cate-
gory for consistency with regulatory classification [40].
Because of differences in potencies between opioids,
clinicians may refer to equianalgesic conversion tables
when switching patients from one opioid to another dur-
ing opioid rotation; conversion ratios by active ingredient
are standardized to morphine. Although legitimate con-
cerns exist about the safety and accuracy of these
tables in routine clinical practice, they serve as a con-
venient tool for epidemiologic research. To have compa-
rable results with previous studies, the conversion ratios
suggested by CDC [41] were used to calculate milli-
grams of morphine equivalents (MME): codeine (0.15),
fentanyl (25.0), hydrocodone (1.0), hydromorphone (4.0),
methadone (3.0), morphine (1.0), oxycodone (1.5), and
oxymorphone (3.0). Total milligrams of MME per
prescription were calculated by multiplying the milligrams
per dosage unit times the quantity of units dispensed
times the conversion factor. The average daily MME per
individual in 2010 was calculated by taking the total milli-
grams and dividing by the days supply, taking into
account overlapping prescriptions. Days supply was pro-
portionally limited, under the assumption of linearity,
for prescriptions written in 2009 for use in 2010, as well
as prescriptions written in late 2010 for use at least
in part in 2011. Benzodiazepine exposure status
was dichotomized as having received dispensed benzo-
diazepines in the 365 days prior to death or end of the
study.
Outcome Definition
Residents who died in 2010 were included if the under-
lying cause-of-death in vital statistics was an uninten-
tional or undetermined drug overdose (ICD-10 codes
X40-X44, Y10-Y14). The role of each drug in the death
was determined by OCME toxicologists according to a
standardized classification system, drawing from investi-
gations at the scene of death, toxicological findings,
available medical records, and interviews. The outcome
was defined as any overdose where at least one of the
eight opioid substances was deemed by the medical
examiner to be involved in primary (the drug was at a
concentration sufficient to have caused the death alone
regardless of other drugs detected) or additive (the drug
was at a concentration not sufficient to have caused the
death alone but acted in an additive manner with other
drugs to have caused the death) roles. Cases were not
included where opioid analgesics’ contribution to death
was circumstantial only, such as when drugs were
present but determined not to have played a role in the
death. Records for 2010 were abstracted into a database
using a standardized extraction form for decedents with
available toxicology results, corresponding to 824 (92%)
deaths identified using vital statistics and ICD-10 codes.
Prescriber Utilization Metric
Using data from the North Carolina Health Professions
Data System [42] the number of potential controlled
substance prescribers was defined as all state-licensed
physicians (n¼ 20,752), nurse practitioners (n¼ 3,679),
physician assistants (n¼ 3,652), and dentists
(n¼ 4,178), and an estimated 100 clinical pharmacist
specialists [43]. The proportion of all potential prescrib-
ers who wrote dispensed prescriptions for opioid anal-
gesics was calculated by dividing the number of unique
NC-registered DEA numbers recorded in the CSRS by
the total number of NC-based licensed clinicians eligible
to obtain a DEA registration number to prescribe con-
trolled substances (n¼ 32,361).
Statistical Analysis
This was a prospective cohort study of all North
Carolina residents in 2010. The state population was
represented by the mid-year population of 9,560,234
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persons estimated by the National Vital Statistics
System [44]. Individuals without a prescription record for
an opioid analgesic in the CSRS contributed unexposed
person-days for all of 2010.
Person-time exposed and unexposed to opioids were
accrued in calendar year 2010 or in the 365 days prior
to overdose death. Data were analyzed according to
intent-to-treat (ITT) principles where an individual was
considered exposed from the date of the first opioid
prescription in 2010 among individuals who did not die
of an overdose. For overdose decedents, first date of
opioid prescription in the 365 days preceding death
was used as the starting point to allow for equal poten-
tial observation time to those who did not have the out-
come. The ITT approach has been suggested for use in
observational safety studies of pharmacotherapy
because it reduces bias arising from excluding those
who stop therapy or are lost to follow-up, is used exten-
sively in the clinical trial setting, and avoids introducing
selection bias during follow-up that would result from
censoring the outcomes of those who changed treat-
ment [45].
MME-stratified incidence rates and incidence rate ratios
were calculated using Poisson regression with person-
days at risk as the offset, implemented with generalized
estimating equations (GEE) to account for repeated
observations of an individual [46–48]. An independent
structure was assigned after initial inspection of the
covariance matrix. Standard errors were calculated
using the Huber-White robust variance method [49],
with the modification of subtracting the number of cova-
riates from the number of observations. Data transfor-
mations and statistical modeling were performed in
Stata/MP 12.1 (College Station, Texas, USA), running
on 8 parallel core processors in a Linux-based comput-
ing system.
Human Subjects Protection
This research was reviewed by the University of North
Carolina Non-Biomedical Institutional Review Board.
Named linkage was conducted by North Carolina
Division of Public Health officials under government sur-
veillance authority.
Results
Opioid Analgesic Prescribing Patterns
A total of 2,182,374 North Carolina residents received
one or more prescriptions for opioid analgesics for use
in 2010, representing 22.8% of the total population. The
frequency distribution of average daily dose across the
population showed that the vast majority of patients
received less than 200 mg of morphine equivalents,
Figure 2. The most commonly dispensed opioid was
hydrocodone (70% of all opioid analgesic patients), fol-
lowed distantly by oxycodone (39%), Figure 3. The
more potent synthetic opioids had the lowest numbers
of prescribers: oxymorphone 6.2% (n¼2,006), metha-
done 16.2% (n¼ 5,256), hydromorphone 24.8%
(n¼ 8,037), and fentanyl 25.0% (n¼ 8,087). Immediate-
release formulations were dispensed to 22.5% of the
population (n¼2,154,949), whereas 1.4% (n¼ 139,520)
received extended-release opioid analgesics.
Immediate-release formulations accounted for 6,535,
257 prescriptions, and extended-release accounted for
858,118 prescriptions, a ratio of about 15-to-2, or
11.6% of all opioid prescriptions were in ER form.
Residents filled prescriptions for opioid analgesics writ-
ten by 28,998 North Carolina-based prescribers.
Prescriptions for opioid analgesics came from 89.6%
(n¼ 28,998) of all licensed clinicians in the state. Opioid
analgesics were the most commonly prescribed type of
controlled substance, but 83.3% (n¼ 26,953) of
licensed clinicians prescribed benzodiazepines, 57.2%
(n¼ 18,518) sleep aids, and 44.8% (n¼14,487) stimu-
lants. Fewer licensed clinicians prescribed extended-
release opioids 40.0% (n¼ 12,939), compared to imme-
diate-release opioids 88.5% (n¼ 28,649).
Only 61,879 patients (2.8%) received more than 150 mg
average daily MME. Of these, 24.9% (n¼ 15,430)
received their entire dose only in IR opioid formulations,
while the remaining received both IR and ER opioids.
Among those receiving more than 150 mg/day MME as
only IR, the median intended duration of use indicated
on the prescription was 4 days (IQR: 1, 30), however
14.1% (n¼ 2,176) were on long-term high-dose therapy
(longer than 182 days).
Overdose Deaths
There were 629 deaths involving opioid analgesics in a
primary or additive role among North Carolina residents
in 2010. Females (n¼234) comprised 37.2% percent of
decedents, and the median age for both sexes was 43
years (interquartile range: 32–51 years). The most com-
mon pharmaceutical opioids involved in overdose
deaths were: oxycodone, methadone, hydrocodone and
fentanyl, Figure 3. Ethanol was involved in 12.2%
(n¼ 77) of overdoses involving opioid analgesics. Heroin
was present in only 1.3% (n¼ 8) of opioid analgesic
overdoses, whereas cocaine was present in 8.4%
(n¼ 53).
Of 2,182,374 patients prescribed opioids, 478 overdose
deaths were reported (0.022%). The rate of overdose
deaths per 10,000 patients with one or more opioid pre-
scription per year (in black, Figure 3) was lowest for
codeine (0.2 per 10,000 patients) and hydrocodone,
and highest for morphine, fentanyl, and oxymorphone.
The opioid substance-specific rates per 10,000 patients
generally followed the proportion of prescriptions written
for ER formulations indicated for chronic pain, and did
not follow the clinical potency as closely. The exception
was oxymorphone which had 54 deaths per 10,000
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patients, despite only being prescribed to 0.5% of
opioid analgesic patients.
Half of all decedents (51%, n¼ 244) had a prescription
for an active current opioid analgesic on the day of
death, ostensibly meaning they were under the care of
a NC prescriber. Among the 629 deaths, 24.0%
(n¼151) had no record of having being dispensed a
solid oral or transdermal opioid analgesic in the 365
days prior to death. Among the 478 decedents who
had received an opioid, 43.1% (n¼ 208) had received at
least one extended-release formulation.
Dose-Dependent Overdose Risk
There were 2,181,847 person-years of opioid analgesic
exposure accrued during the study period. Incidence
rates appeared to increase gradually, and stayed ele-
vated beyond 200 mg/day MME, Figure 4 and Table 1.
No distinct threshold was observed at 100 mg/day
MME or 120 mg/day MME.
The percent of all opioid analgesic recipients who were
also prescribed a benzodiazepine in the past year was
80.0% (n¼1,747,166). Benzodiazepines were deter-
mined to be involved by medical examiners in 61.4%
(n¼386) of overdose deaths involving opioid analgesics.
Rates of overdose death were about ten times higher
among those receiving benzodiazepines and opioids
concurrently (7.0 per 10,000 person-years, 95 percent
CI: 6.3, 7.8), compared to only opioid analgesics (0.7
per 10,000 person years, 95 percent CI: 0.6, 0.9),
Figure 5. When compared to patients receiving the
same MME of opioid analgesics, differences in mortality
rates among those receiving benzodiazepines was
greater at higher opioid analgesic doses. At the lowest
stratum, >0 to 74.9 mg/day average daily MME, the
rate difference was 2.8 per 10,000 person-years,
increasing to 45.8 per 10,000 person-years at the high-
est stratum of 300 to 5,000 mg/day average daily MME.
Discussion
This study reports findings from the largest known pro-
spective cohort study of opioid analgesic use in routine
medical practice. While there may be a place for high-
dose opioid formulations in modern medicine, previous
research provided little insight on risks above 100 MME.
These results extended the knowledge of the relation-
ship between opioid analgesic use and mortality by clar-
ifying dose-specific risks at higher doses. The dose-
dependent relationship between opioid analgesic dose
and overdose mortality is strongly influenced by concur-
rent benzodiazepine exposure, especially in the pres-
ence of higher opioid doses.
Overdose mortality rates rose gradually at lower doses,
and increased gradually at doses greater than 200 mg
average daily MME. Like previous studies, a dose–
Figure 2 Distribution of average daily morphine equivalent dose. Histogram depicting average daily dose of opioid
analgesics in terms of morphine equivalents (n¼2,182,374 patients).
Dasgupta et al.
90
D
ow
nloaded from
 https://academ
ic.oup.com
/painm
edicine/article-abstract/17/1/85/1752837 by The U
niversity of N
orth C
arolina at C
hapel H
ill Libraries user on 15 August 2019
response relationship between MME and mortality risk
was observed, but there is new evidence that the shape
of the curve is not linear. Unlike previous studies, there
was no meaningful inflection of the incidence rate at
100 mg/day average daily MME [25]. However, there
appeared to be relatively small additional risk of over-
dose death after patients reach 200 mg average daily
MME, relative to the lowest strata, on the log-linear
scale. Theoretically, opioid tolerance may be part of the
explanation. Increased opioid tolerance results in a right-
ward shift of the median effective dose, which may be
accompanied by a corresponding shift in the median
toxic dose, resulting in a broader or shifted therapeutic
window where medication errors may be less likely to
lead to respiratory depression.
A surprising finding was that benzodiazepines had
been prescribed in the previous year to eight-out-of-
ten patients receiving opioid analgesics, despite wide-
spread clinical knowledge of the risk of respiratory
depression and electronic access to a controlled
substances prescription monitoring program. This is in
comparison to 5% of the adult US population receiving
benzodiazepines [50]. A recent study among Medicaid
patients in Washington state found that 44.5% of
methadone poisoning decedents and 48% of other
opioid poisoning decedents had sedative (e.g., benzo-
diazepine) prescriptions in the month before death [34].
Another recent study among United States military vet-
erans found that 27% of patients who received opioid
analgesics also received benzodiazepines, and that
49% of overdose decedents had concurrent opioid
analgesic and benzodiazepine prescriptions [51]. The
differences between studies are likely due to time defi-
nitions used. The risk of respiratory depression from
concurrent benzodiazepine and opioid analgesic use is
widely known in clinical settings, and increased mortal-
ity risk has been documented among drug users [37].
Cross-sectional mortality surveillance studies [52] have
also noted the presence of benzodiazepines among
overdose deaths; one study found that benzodiaze-
pines were involved in 78.5% of deaths involving
Figure 3 Percents of prescribers, prescriptions, patients receiving opioid analgesics, and overdose deaths, by active
ingredient and formulation type. Numbers in parenthesis in the figure represent the approximate relative potency to
morphine. Columns 1, 3, 4, and 5 do not sum to 100% because individuals could appear in more than one category.
Column 1 represents the percent of total opioid analgesic prescriptions (column 2) that were extended-release or
long-acting formulations (n¼858,118), by active opioid ingredient. The denominator for column 2 is the total number
of unique recipients of opioid analgesics (n¼ 2,182,374). The denominator for column 3 is the number of deaths
involving opioid analgesics in a primary or additive role (n¼ 629), and column 4 is the rate of overdose deaths per
10,000 patients per year expressed with the number of unique opioid analgesic patients as the denominator. The
denominator for column 5 is all licensed clinicians in North Carolina including doctors, nurse practitioners, physician
assistants, and clinical pharmacists (n¼ 32,361). * Methadone rate is not presented because methadone involved in
overdose deaths is not differentiated by formulation in medical examiner data, and include mentions of methadone in
tablet form (pain management) as well as liquid (management of opioid dependence).
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psychotherapeutic drugs. However, there is limited
information as to how commonly the two central nerv-
ous system depressants are coprescribed in large pop-
ulation samples. This situation differs considerably from
opioid analgesic efficacy clinical trials that exclude
patients with psychiatric diagnoses for conditions rou-
tinely treated with benzodiazepines (e.g., anxiety, etc.)
in the United States.
The underlying prevalence of chronic pain and the avail-
ability of treatment should also be considered. The
authors of a telephone-based study of North Carolina
households reported that approximately 10% of adults
suffered from chronic disabling back pain [53]. There
are concerns that limiting the number of clinicians who
prescribe ER opioids may adversely affect pain patients’
ability to achieve analgesic relief, construed as an
“access to care” problem, especially among racial and
ethnic minorities [54]. While “access to care” is a com-
monly described concern in pain management, there is
no accepted way to quantify it. While increased pre-
scribing by primary care doctors has led to wider
access to pain treatment, a general concern is that
non-specialized clinicians may not have been
adequately trained to prescribe these medications safely
[55]. This analysis is one of the first to quantify the
extent of prescribing of ER and IR opioid analgesics
among all licensed clinicians in a population-based
study, which provides a clearer picture of what access
to opioid therapy may mean at a population level. While
it may not be surprising that 89.6% of licensed clinicians
prescribe opioid analgesics, that 40.0% had prescribed
an ER opioid was higher than expected. This study also
found that 22.8% of the population received an opioid
analgesic in 2010, and 1.4% received an ER opioid
analgesic, consistent with the national estimate of 1.2%
for 2009 presented by FDA at an Advisory Committee
based on commercially available data [56] (and in line
with utilization patterns from other high-income coun-
tries [57]). As a society we urgently need to understand
what level of ER opioid prescribing would strike the cor-
rect balance between access to care concerns and
overdose risk.
Many ER opioid analgesics have approved single unit
doses greater than 100 mg/day MME. There is limited
Figure 4 Incidence rates
and incidence rate ratios
for overdose deaths involv-
ing opioid analgesics, by
average daily milligrams of
morphine equivalents. The
incidence rate appears to
be distinctly elevated at
doses greater than 200 mg
average daily MME, top
graph. Dotted lines are the
bounds of the 95 percent
confidence intervals (CI). In
the bottom graph, the
reference group for inci-
dence rate ratios (IRR) is
>0 to 19.9 mg of average
daily milligrams of morphine
equivalents, represented by
the solid black square.
IRRs and CIs (dotted lines)
were estimated using
Poisson regression, with
person-days of exposure
accrued in an intent-to-
treat-type manner. The ver-
tical axis in the lower graph
is plotted on the log10
scale. Average daily MME
are plotted at the midpoint
of the each category range;
the last point includes 500
through 5,000 mg/day.
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Table 1 Incidence rates and ratios for overdose deaths involving opioid analgesics, by average daily
milligrams of morphine equivalents
Deaths Person-Years n
Rate per
10,000
Person-Years
95%
Confidence
Interval
Incidence
Rate
Ratio
95%
Confidence
Interval
Unexposed 151 3,554,850 7,377,860 0.34 0.29, 0.40 0.57 0.44, 0.73
>0 to 39.9 mg/day 98 1,305,835 1,305,969 1.3 1.0, 1.5 1
40 to 59.9 mg/day 90 457,227 457,322 3.2 2.6, 4.0 2.6 2.0, 3.5
60 to 79.9 mg/day 47 213,816 213,868 3.7 2.7, 4.9 2.9 2.1, 4.1
80 to 99.9 mg/day 34 72,448 72,483 7.4 5.3, 10.3 6.2 4.2, 9.2
100 to 119.9 mg/day 23 45,536 45,559 8.3 5.5, 12.4 6.7 4.3, 10.6
120 to 139.9 mg/day 22 20,699 20,721 14.4 9.5, 21.8 14.1 8.9, 22.5
140 to 159.9 mg/day 14 14,586 14,599 13.8 8.2, 23.3 12.8 7.3, 22.4
160 to 179.9 mg/day 15 6,769 6,784 26.9 16.2, 44.5 29.5 17.1, 50.7
180 to 199.9 mg/day 11 9,604 9,615 14.8 8.2, 26.6 15.2 8.2, 28.4
200 to 249.9 mg/day 24 11,653 11,678 24.6 16.5, 36.7 27.4 17.5, 42.8
250 to 299.9 mg/day 20 7,406 7,425 31.6 20.4, 48.9 35.9 22.2, 58.0
300 to 349.9 mg/day 17 4,495 4,512 43.9 27.3, 70.6 50.2 30.0, 84.0
350 to 399.9 mg/day 17 3,563 3,580 55.5 34.6, 89.2 63.2 37.8, 105.7
400 to 499.9 mg/day 14 3,527 3,541 45.2 26.8, 76.2 52.7 30.1, 92.2
500 to 5,000 mg/day 32 4,684 4,718 80.0 56.7, 113.0 90.4 60.7, 134.6
Total 629 5,736,696 9,560,234
Figure 5 Incidence rate ratios
for overdose deaths involving
opioid analgesics, by benzo-
diazepine prescription status.
Benzodiazepine exposure
was determined by receipt of
at least one prescription for a
benzodiazepine in 365 days
prior to death or end of the
study, versus those who had
no record of such a prescrip-
tion. Reference group for inci-
dence rate ratios (IRR) is >0
to 19.9 mg/day of average
daily milligrams of morphine
equivalents (MME). Grey lines
are the bounds of the 95 per-
cent confidence interval (CI).
IRRs and CIs were estimated
using Poisson regression,
with person-days of exposure
accrued in an intent-to-treat-
type manner. The vertical axis
is plotted on the log10 scale.
Average daily MME are plot-
ted at the midpoint of the
each category range; the last
point includes 500 through
5,000 mg/day.
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information from general practice settings to guide clini-
cal decisions at these higher doses. The increase in the
160–179.9 mg/day MME interval represents risk from
the most commonly prescribed dose strengths of the
fentanyl patch. Methods for calculating MME which do
not take into account overlapping prescriptions
(e.g., total mg MME for all prescriptions divided by the
sum of days supply) underestimate the risk in this spe-
cific category. Therefore, it is critical to account for over-
lapping prescriptions, and justifies taking a person-time
approach to MME calculation with intent-to-treat
principles.
Comparing to the most similar published study to ours,
the range of observed effect measures (IRR 2.6 through
6.7 for categories up to 119.9 mg/day) were lower than
the odds ratio (OR) reported by Paulozzi et al. for aver-
age daily MME of 40 to 120 mg/day (OR 12.2, 95% CI:
9.2, 16.0). Our effect measures were greater than theirs
(OR 11.3, 95% CI: 8.1, 15.8) for the highest categories,
with IRR ranging from 16.6 through 90.4. That study
combined unexposed and low-exposure individuals in
the referent category, but also included suicides and
deaths involving only illicitly manufactured drugs, limiting
direct comparison. Despite this, the curves plotting rela-
tive risk against average daily MME (Figure 3) from both
studies were strikingly similar in shape (e.g., Figure 2 in
Paulozzi et al.), although the current study provides
greater resolution at higher doses.
It is important to consider that patients at higher doses,
especially those on stable for long periods of time, may be
chronic pain patients under the care of a physician. Of
course, the possibility exists that some higher dose patients
may be diverting opioids or exhibit drug-seeking behavior.
Given that 24% of decedents had no prescription opioid
analgesic history in the year preceding death, it is clear
that some of the drugs used in overdose deaths are
obtained through social sharing outside of sanctioned
medical use. This is similar to the 26% and 16% of meth-
adone and other opioids overdose decedents, respec-
tively, not having opioid prescriptions in a Washington
state Medicaid study [34]. We found that half of all North
Carolina overdose decedents had an active prescription
at the time of death, similar to Washington findings of
59% among methadone overdose decedents and 43%
among other opioid overdose decedents in the week
prior to death [34]. The findings suggest that history of
opioid analgesic prescription is neither necessary nor
causal to experience an overdose, but that opioid avail-
ability from a licensed clinician is one factor in a likely
complex individual risk environment [58–60].
The study has limitations. First, the statistical models
assumed continuous risk during exposed and unex-
posed time. This assumption is unlikely to be tenable at
higher opioid doses; the riskiest time may be shortly
after the initiation of therapy. Previous duration of ther-
apy was also not taken into account. External factors
could have influenced overdose mortality during our
observation period. Efforts to increase access to treat-
ment for opioid dependence, prescriber education pro-
grams for pain management, and harm reduction
programs are known to have existed in North Carolina
in 2010 but in their infancy [61], as well as changes in
formulation of one opioid analgesic [62]. All studies
relying on medical examiner or vital statistics data are
subject to limitations about ascribing causality for the
involvement of drug substances [63,64]. Medical exam-
iner determination of death inherently contains an ele-
ment of subjective clinical judgment. By excluding
deaths were an opioid was simply present, we attempt
to mitigate some of the effects of this source of bias. As
with the other studies on this topic, the possibility exists
that patients obtained opioid analgesics from other
states or from outside medical distribution channels.
Similarly, the assumption was made that patients on
average took the entire dispensed prescription as
instructed. Therefore the actual exposure may have dif-
fered somewhat from that prescribed.
Another limitation stems from the fact that many high
dose IR opioids contain acetaminophen, and overdose
deaths may have occurred from hepatic injury [65].
According to North Carolina vital statistics data, there
were 18 deaths in 2010 among all residents that were
possibly related to acetaminophen toxicity (ICD-10
codes: K71.1, Y45.5, Y10, X40, T39.9, T39.1), with
acknowledgment that there may be underreporting of
cases and diagnostic suspicion bias which would cause
the opioid component of a combination analgesic to be
singled out for causal attribution. Only two of these
deaths included codes consistent with overdose, but
both were deemed to be suicides and were not
included in our study. Therefore, the relative contribution
of hepatic toxicity appears to be low.
The greatest limitation of this study stems from the
inherent question of exchangeability when comparing
patients at different doses of the same medication in
observational studies. Patients receiving higher doses
are more likely to have more serious illnesses which
may necessitate higher doses. Even though no addi-
tional covariate information was available to adjust for
the likelihood of receiving treatment, the importance of
describing opioid prescribing in a large population-
based observational study has the benefit of offering
insight into routine medical practice that has broad pol-
icy implications.
Deaths involving opioid analgesics result from physio-
logic, genetic, and behavioral factors, compounded by
broader social determinants such as health literacy,
poverty, access to healthcare, and further upstream
causes of painful conditions from injuries, cancer and
violence [58,66]. These characteristics may also influ-
ence the likelihood of receiving a prescription for an
opioid analgesic. Data on these potential confounders
are not routinely available at an individual level in large
population-based studies, and were thus not controlled
for in this study.
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Future directions for study will include duration of time
on opioid therapy and the specific type and dose of
benzodiazepines involved in overdose deaths.
Conclusion
This study is the largest population-based cohort study
published to date. It quantifies the dose-response rela-
tionship between opioid prescribing and overdose mor-
tality, especially at higher doses than previously
examined. Higher doses of opioid analgesics were asso-
ciated with increased overdose risk, however, there
were smaller incremental increases in risk above 200
mg average daily MME. Much of the risk at higher
doses appears to be associated with co-prescribed
benzodiazepines. As a society we urgently need to
understand what level of ER opioid prescribing would
strike the correct balance between access to care con-
cerns and dangerous, yet common, situations created
by ignoring known drug interactions at the point of care.
There is also a need to objectively understand and
quantify what benefits patients receive from ER versus
IR opioid analgesics.
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